Research AZ’s blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER saysBy Healthcare Propulsion StaffAugust 13, 20260 AstraZeneca’s newly approved, first-in-class hypertension drug Baxfendy does not clear the bar for effectiveness relative to its price, according to…
